Keyword: Johnson & Johnson
J&J chief Alex Gorsky has assured plenty of critics that its talc products are safe, but he's not interested in explaining to Congress.
New "gold standard" data could further increase doctors' confidence in multiple myeloma med Darzalex, Johnson & Johnson says.
In an effort to stop an Ebola outbreak that has claimed 2,200 lives at the Rwanda border, J&J is shipping 200,000 doses of its vaccine to the country.
AbbVie and Roche have fielded their fair share of questions about how well their fixed-duration regimen of Venclexta and Rituxan can keep CLL at bay.
Already facing thousands of civil suits, Johnson & Johnson and Teva could be facing a criminal investigation into their opioid businesses.
A Pennsylvania appeals court upheld a 2016 Risperdal verdict against Johnson & Johnson worth $70 million in actual damages.
Imbruvica has enjoyed a nice run in previously untreated CLL over the last few years. But major competition is here in the form of AZ's Calquence.
Pennsylvania's Supreme Court revived thousands of lawsuits alleging the antipsychotic med Risperdal caused males to develop breasts.
While many of the decade's M&A deals worked out for the buyers, others didn't deliver on their promises. Here, we feature 15 of those deals, including Bayer's Monsanto buy, Teva's purchase of Allergan's generics, AbbVie's Synageva pickup and many others.
